LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results ...

In this 5 Minutes With interview, Kathryn Nichol of LivaNova shares her insights into neuromodulation and her passion for the ...

LivaNova’s ‘strengthened’ commitment to neuromodulation is shining brightly today, as the London-based company has secured FDA approval for an IDE. The company now has the green light to move forward ...

LivaNova PLC, a medical technology company listed in the US, continues to expand its neuromodulation portfolio while navigating competitive pressure in cardiac surgery. For investors, the split ...

LivaNova delivered second-quarter results that offered refreshingly positive, though not unanticipated, growth against the weak prior-year period characterized by shelter-at-home orders. We’ve raised ...

Since my last article, which you can find here, we've seen LivaNova deliver these outsized returns for a few reasons. In this article, I'll be going through those reasons, I'll be providing an ...

LivaNova focuses on Cardiopulmonary and Neuromodulation devices, with strong growth in Cardiopulmonary sales and a flat performance in Neuromodulation. The company faces risks from a $363 million ...

Livanova plc is exploring strategic options for its cardiac rhythm management (CRM) unit. The London-based company's CRM business generated $249.1 million in net sales in 2016. Key products in the ...

Technology at the Neural Interface has published the full 36-month results from the CORE-VNS study, the first long-term effectiveness evaluation of contemporary VNS Therapy? devices in people with ...